Category Archives: Tenofovir

  1. South African Clinicians Outline Best Treatment for Prevention Practices

    via, by Mia Malan South African guidelines for the preventative use of HIV medication by men who have sex with men who are not infected with the virus are to be published in the peer-reviewed academic publication, Southern African Journal of HIV Medicine, this month. The treatment, pre-exposure prophylaxis (Prep), consists of an antiretroviral (ARV) pill Read More >>

    Africa, ARV, HIV, hiv prevention, MSM, PrEP, South Africa, Tenofovir
  2. FDA Hearing on Truvada as PrEP – Watch the Webcast!

    On May 10, 2012 the FDA Antiviral Drug Advisory Committee strongly recommended that emtricitabine/tenofovir disoproxil fumarate (TDF/FTC or Truvada) be approved for use as pre-exposure prophylaxis (PrEP) among sexually active adult men and women – particularly gay men and other MSM, serodiscordant heterosexual couples, and other individuals at high risk. It is likely the FDA will follow Read More >>

    FDA, HIV/AIDS. pre-exposure prophylaxis, MSM, pre-exposure prophylaxis, PrEP, risk, Tenofovir, Truvada
  3. AIDSmeds: Rectal Microbicide Shows Better Safety in Laboratory Study

    via AIDSmeds Laboratory testing of a modified version of the Viread (tenofovir) microbicide gel provides further evidence that it may be safe for rectal use, according to a paper published online ahead of print by the Journal of Antimicrobial Chemotherapy. The encouraging results contribute to a better understanding of the gel’s tolerability, already evident in preliminary findings Read More >>

    Microbicide Trials Network, MTN 007, MTN 017, rectal microbicide, research, Tenofovir, Truvada
  4. Reformulation of Tenofovir Vaginal Gel Safe for Rectal Use

    via A change in the formulation of tenofovir gel, an anti-HIV gel developed for vaginal use, may make it safer to use in the rectum, suggests a study published online this week in the Journal of Antimicrobial Chemotherapy. In laboratory tests of rectal tissue, researchers from the Microbicide Trials Network (MTN) found that the reformulated gel Read More >>

    2012, CROI, Microbicide Trials Network, Microbicides, MTN, MTN 007, rectal microbicide, Tenofovir, vaginal microbicide
  5. PrEP Project Initiative Starting Throughout California

    via California HIV/AIDS Research Program In April 2012, the California HIV/AIDS Research Program (CHRP) of the University of California awarded grants totaling $11.8 million to three collaborative teams of investigators to test a potential HIV prevention medication among high-risk HIV-uninfected persons in several communities throughout California. The studies also will examine new strategies to engage and retain Read More >>

    ARV, Gilead, MSM, pre-exposure prophylaxis, PrEP, prevention, Tenofovir, Truvada
  6. Gene Expression: How Proteins Are Made and Our Cells Functions

    By Natasha Thakkar, IRMA Intern In the IRMA teleconference held on March 15th, 2012, Dr. Ian McGowan explained, the effects of 1% tenofovir gel on gene expression and regulation (click here for his slides). There were many questions on the call about gene expression and gene regulation, and because I studied Molecular and Cellular Biology at the Read More >>

    gene expression, genes, proteins, teleconference, Tenofovir
  7. NYT: Setback on PrEP Results May Have Been Misunderstood

    via The New York Times, by Donald G. McNeil Jr. The failure of a daily pill to protect healthy African women against AIDS may not have been the pill’s fault but the women’s reluctance to take it, scientists at an important AIDS conference in Seattle were told this week. Last April, a promising trial of “pre-exposure prophylaxis” Read More >>

    2012, clinical trials, CROI, pre-exposure prophylaxis, PrEP, Tenofovir, Truvada
  8. Two Studies Show the Importance of Adherence in PrEP at CROI 2012

    via, by Gus Cairnes Adherence makes all the difference to the efficacy of pre-exposure prophylaxis (PrEP), the 19th Conference on Retroviruses and Opportunistic Infections (CROI) heard today. Further data were presented from two trials of PrEP (giving anti-HIV drugs to HIV-negative people to prevent infection), which announced dramatically different results last year. In April 2011, the Read More >>

    CROI, FEM-PrEP, HIV/AIDS. pre-exposure prophylaxis, Partners PrEP, pre-exposure prophylaxis, PrEP, Tenofovir, Truvada
  9. CROI 2012: iPrEx Researchers Test Dosage of PrEP

    via, by Gus Cairns Further testing of drug levels in the blood and immune cells of gay men participating in the iPrEx trial of tenofovir/FTC (Truvada) pre-exposure prophylaxis (PrEP) has found that HIV infection in men assigned to Truvada was associated with a lapse in taking the drug after initially adhering reasonably well, rather than never Read More >>

    CROI, iPrEx, PrEP, Tenofovir, Treatment, Truvada
  10. CROI Reports Rectal Tenofovir Trial Results

    via, by Gus Cairns A gel containing 1% tenofovir formulated specifically for rectal use was much better tolerated than gels used in previous rectal microbicide trials when used in a safety study in 65 HIV-negative men and women, the 19th Conference on Retroviruses and Opportunistic Infections (CROI) heard yesterday. The gel was also compared with other Read More >>

    clinical trials, CROI, Microbicide Trials Network, Microbicides, MTN 007, rectal microbicide, Tenofovir